Restylane SubQ Lidocaine 2ml dermal filler 의 안전성 경고

Department of Health에 따르면, 해당 안전성 경고 는 Hong Kong 에서 Q-Med AB 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 날짜
    2013-02-21
  • 사례 국가
  • 사례 출처
    DH
  • 사례 출처 URL
  • 비고 / 경고
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • 데이터 추가 비고
    Press release
  • 원인
    Recall of restylane subq lidocaine 2ml dermal filler the department of health (dh) today (february 21) drew public attention to the recall of a dermal filler, restylane subq lidocaine 2ml (batch numbers: 11907 and 11516), due to defects in the sealing of the package which might compromise the external sterility of syringes containing the product. the dh received notification from the product's local supplier, galderma hong kong limited, that the swedish manufacturer, q-med ab, had initiated a recall of the above product. "according to the manufacturer, the decision to recall the affected products from the market is due to defects in the sealing of the package. while the sterility of the content inside the syringe is unaffected, defects in the package mean that the external sterility of the syringe can no longer be guaranteed," a dh spokesperson explained. "further investigation into the local supplier's product distribution records shows that it has distributed the affected products, comprising about 170 pieces, to medical clinics and beauty centres from june 2012 to february 2013," the spokesperson added. so far, the dh has not received any adverse event reports related to the products. the dh will closely monitor the recall. in case members of the public have the products in their possession, they can contact galderma on its hotline (2238 0900) for public enquiries. the spokesperson also reminded the public that anyone who is in doubt or feeling unwell after having used the product should consult health-care professionals. the dh has informed public and private hospitals and relevant medical associations about the issue. ends.

Device

  • 모델명 / 제조번호(시리얼번호)
  • 제품 설명
    Press release: Recall of Restylane SubQ Lidocaine 2ml dermal filler
  • Manufacturer

Manufacturer